Previous close | 0.0500 |
Open | 0.1000 |
Bid | 0.0500 |
Ask | 0.1000 |
Strike | 3.00 |
Expiry date | 2024-07-19 |
Day's range | 0.0500 - 0.1300 |
Contract range | N/A |
Volume | |
Open interest | 1.69k |
PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and
The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for the Study of Pain, and features original research on the nature, mechanisms and treatment of pain.This Phase 3 study met primary and important key secondary endpoints, with SP-102 (SEMDEXA™) treatment, decreasing pain intensity for over a month in sciatica patients and resulting in statistically signi
One thing we could say about the analysts on Scilex Holding Company ( NASDAQ:SCLX ) - they aren't optimistic, having...